PubMed · 14280621
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
T FRIIS. 1965-05-06. [THIOCYANATE SUPPRESSION TEST IN THYROID DISEASE].. https://pubmed.ncbi.nlm.nih.gov/14280621/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
Recombinant human thyroid-stimulating hormone (rhTSH), used to enhance diagnostic radioiodine whole body scanning and thyroglobulin testing, has dramatically altered the management of patients with thyroid cancer. Withdrawal from thyroid hormone suppression therapy and subsequent hypothyroidism is no longer the only safe and effective method for thyroid cancer surveillance. Currently, rhTSH is only approved for the monitoring of low-risk patients with well-differentiated thyroid cancer and radioactive iodine administration, in selected cases. Additional applications of rhTSH include enhancing the sensitivity of positron emission tomography in thyroid cancer, the management of multinodular goiter, and dynamic testing of thyroid reserve. The diagnostic and therapeutic role of rhTSH in these areas is discussed in this review.
In this study we describe the localization of MRP1 in normal and hyperplastic thyroid tissues. To demostrate this protein we have used the enzyme imunohistochemical method with monoclonal antibody MRPm6. We have found MRP1 to be present in follicular epithelial cells of normal thyroid tissue and higher expression in the same cells of hyperplastic thyroid tissue. The brown colour of the diaminobenzidine reaction product allowed us to define the distribution of stain clearly. (Fig. 4, Ref. 16.)